



FOR IMMEDIATE RELEASE

Regeneron Pharmaceuticals Licenses OriGene TrueClone™ Collection

Rockville, MD April 26, 2005 – OriGene Technologies Inc. today announced that Regeneron Pharmaceuticals has licensed a subscription based access to their TrueClone™ Collection of 24,000 full-length human cDNAs suitable for transfection and high throughput functional analyses.

"We are pleased to formalize our relationship with OriGene," said Drew Murphy, Vice President of Target Discovery for Regeneron. "We believe that full-length cDNAs isolated from cDNA libraries are the most reliable source of authentic coding regions for our critical applications. The OriGene True Clone collection has proven to be an excellent source of full-length human cDNAs for use in Regeneron's protein expression and target validation platforms."

The OriGene TrueClone™ Collection of 24,000 cDNAs represents the world's largest commercial source of human full-length cDNAs. All transcripts in the TrueClone™ Collection are isolated directly from primary cDNA libraries, therefore devoid of PCR artifacts. Each cDNA clone is housed in expression vectors suitable for transfection and protein expression. The comprehensive nature of the TrueClone™ Collection and the uniformity and expression-readiness of the cloning vector uniquely enables a systems biology approach to high-throughput screening and functional studies.

"OriGene's mission is not only to build the most comprehensive collection of human full-length cDNAs, but also to make it a scientifically useful platform to enable systematic studies of human gene functions to all researchers," said Karl Kovacs PhD, Vice President of Alliance Management at OriGene. "We are especially delighted to have the opportunity to work and interact with such innovative and high-caliber scientists at Regeneron".

About Regeneron Pharmaceuticals

Regeneron is a biopharmaceutical company that discovers, develops and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer and eye diseases, rheumatoid arthritis and other inflammatory conditions, asthma, and obesity and has preclinical programs in other diseases and disorders. Regeneron corporate headquarters are in Tarrytown, NY. For more information, please visit <http://www.regn.com>.

About OriGene Technologies

OriGene provides innovative technologies for large-scale gene function analyses. OriGene's flagship product is the TrueClone™ Collection, a searchable source of cDNA clone containing over 24,000 human full-length cDNA clones suitable for transfection and protein expression. More information about OriGene Technologies and their products can be found at the company's web site at <http://www.origene.com>.

For additional information regarding this announcement, please contact:

Rich Hamer, Ph.D.
Business Development
OriGene Technologies 240-620-5781
rhamer@origene.com